CN119136794A - 法尼醇x受体激动剂的用途 - Google Patents

法尼醇x受体激动剂的用途 Download PDF

Info

Publication number
CN119136794A
CN119136794A CN202380035124.0A CN202380035124A CN119136794A CN 119136794 A CN119136794 A CN 119136794A CN 202380035124 A CN202380035124 A CN 202380035124A CN 119136794 A CN119136794 A CN 119136794A
Authority
CN
China
Prior art keywords
patient
compound
pharmaceutically acceptable
score
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380035124.0A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·卡博萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigma Ag
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CN119136794A publication Critical patent/CN119136794A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202380035124.0A 2022-04-21 2023-04-21 法尼醇x受体激动剂的用途 Pending CN119136794A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US63/333,287 2022-04-21
US202263381752P 2022-10-31 2022-10-31
US63/381,752 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (1)

Publication Number Publication Date
CN119136794A true CN119136794A (zh) 2024-12-13

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380035124.0A Pending CN119136794A (zh) 2022-04-21 2023-04-21 法尼醇x受体激动剂的用途

Country Status (10)

Country Link
US (1) US20250288600A1 (cg-RX-API-DMAC10.html)
EP (1) EP4511012A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025513289A (cg-RX-API-DMAC10.html)
KR (1) KR20250006156A (cg-RX-API-DMAC10.html)
CN (1) CN119136794A (cg-RX-API-DMAC10.html)
AU (1) AU2023257308A1 (cg-RX-API-DMAC10.html)
CA (1) CA3249500A1 (cg-RX-API-DMAC10.html)
IL (1) IL315941A (cg-RX-API-DMAC10.html)
MX (1) MX2024012966A (cg-RX-API-DMAC10.html)
WO (1) WO2023205447A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
US12677339B2 (en) * 2022-11-14 2026-07-07 Intel Corporation Sensing by proxy (SBP) termination frame with termination control field

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EA038632B1 (ru) * 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
IL271343B2 (en) * 2017-06-23 2023-12-01 Intercept Pharmaceuticals Inc Methods and intermediates for the preparation of bile acid derivatives

Also Published As

Publication number Publication date
IL315941A (en) 2024-11-01
JP2025513289A (ja) 2025-04-24
AU2023257308A1 (en) 2024-10-10
EP4511012A2 (en) 2025-02-26
WO2023205447A3 (en) 2024-04-04
MX2024012966A (es) 2024-11-08
KR20250006156A (ko) 2025-01-10
WO2023205447A2 (en) 2023-10-26
EP4511012A4 (en) 2026-06-24
CA3249500A1 (en) 2023-10-26
US20250288600A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
JP5094384B2 (ja) Ｆｘｒリガンドを使用する線維症の処置
Cobbold et al. Rifaximin in non‐alcoholic steatohepatitis: an open‐label pilot study
JP2020147585A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
Kuiken et al. Biomarkers and non-invasive tests for gastrointestinal mucositis
JP2020530840A (ja) 胆汁うっ滞性疾患を治療するための組成物及び方法
US20220143003A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20250288600A1 (en) Uses of farnesoid x receptor agonists
CN107613986A (zh) 用于组合疗法的药物组合物
Polyzos et al. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
JP2024544538A (ja) ＴＨＲ－βアゴニストによる肝障害の治療
CN115605198B (zh) 脂肪性肝病的治疗药
KR20200017487A (ko) 비알코올성 지방간염 치료를 위한 리코플리고진
Oleszczuk et al. Regenerative capacity differs between micro-and macrovesicular hepatic steatosis
EP4611888A1 (en) Uses of farnesoid x receptor agonists
Lin et al. Increased serum soluble tumor necrosis factor receptor levels are associated with insulin resistance in liver cirrhosis
EL-Sehemy, Mona S.*, Al-Saaran, Amina M.*, Baddour, Nahed M.**, Adam, Ahmed G.* & Moez Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis
EP4125988A1 (en) Detection and treatment of intestinal fibrosis
Furini et al. Ketogenic state is able to improve testosterone serum levels-a meta-analytic approach
HK40118289A (en) TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST
Morita et al. 699 Nateglinide improves non-alcoholic steatohepatitis (NASH) with type 2 diabetes
Vikse et al. B. Renal Disease and Failure
HK1242970A1 (en) Pharmaceutical compositions for combination therapy
EA042686B1 (ru) Способ лечения неалкогольного стеатогепатита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20260317

Address after: Bologna, Italy

Applicant after: Alpha Sigma AG

Country or region after: Italy

Address before: new jersey

Applicant before: INTERCEPT PHARMACEUTICALS, Inc.

Country or region before: U.S.A.

TA01 Transfer of patent application right